マウスモデル市場 – 2030年までの世界予測

本調査レポートでは、マウスモデル市場をモデルタイプとサービス別（モデルタイプ（近交系マウス、遺伝子組み換えマウス、ハイブリッド/コンジェニックマウス、非近交系マウス、繁殖サービス、凍結保存サービス、再誘導体化サービス、検疫サービス、その他のサービス））、用途別（医薬品の発見と開発、研究用途、個別化医療）、技術別（CRISPR/Cas9、マイクロインジェクション、胚性幹細胞注入、核移植、その他の技術）、治療領域別（腫瘍学、神経学、免疫学、代謝性疾患、心血管疾患、その他の治療領域）、製品エンドユーザー別（製薬およびバイオテクノロジー企業、学術研究機関、CROおよびCDMO）、サービスエンドユーザー別（製薬およびバイオテクノロジー企業、政府および生物医学研究機関、CDMO）、地域別（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。

マウスモデル市場は、2025年の17億米ドルから2030年には27億4000万米ドルに達すると予測されており、予測期間中は年平均成長率（CAGR）10.0%で成長します。この市場の成長は、遺伝的および生理学的汎用性による前臨床研究におけるマウスモデルの採用増加、マウス臨床試験（MCT）の需要増加、腫瘍学における個別化医療の需要増加、そして遺伝子工学の進歩など、複数の要因によって牽引されています。バイオメディカル研究におけるCRISPRの活用と、疾患特異的モデルの需要増加も、予測期間中の市場成長に寄与すると予想されます。

The mice model market is projected to reach USD 2.74 billion by 2030 from USD 1.70 billion in 2025, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by several factors, such as rising adoption of mice models in preclinical studies due to genetic & physiological versatility; the increasing demand for mouse clinical trials (MCTs); the rising demand for personalized medicine in oncology; and advancements in genetic engineering. Utilization of CRISPR in biomedical research and the increasing demand for disease-specific models are also expected to contribute to market growth during the forecast period.

By model type, the inbred mice segment accounted for the largest share of the market in 2024.

The market is segmented by model type into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. In 2024, the inbred mice segment accounted for the largest share of the mice model market. The large share of the inbred mice segment is attributed to the ability of inbred strains to provide genetic uniformity for preclinical studies, standardized breeding protocols that enable scalable production, and supply chains that support continuous availability. Regulatory frameworks at national and international levels recognize inbred strains as reference models for efficacy and safety assessment, and centralized breeding facilities implement quality control measures to maintain strain integrity. Adoption of inbred mice spans pharmaceutical and biotechnology companies and academic and government research institutions, where controlled genetic backgrounds reduce experimental variability.

By application, the drug discovery & development segment accounted for the largest share of the market in 2024.

The mice model market is segmented into drug discovery & development, research applications, and personalized medicine. In 2024, the drug discovery & development segment accounted for the largest share of the market. Mouse models are deployed in target validation assays to confirm the relevance of molecular targets, in lead optimization studies to compare pharmacodynamic profiles, and in efficacy evaluations to measure treatment responses under controlled conditions. Safety pharmacology protocols—cardiovascular, respiratory, and central nervous system endpoints—rely on telemetry recordings and behavioral assays conducted in mice. At the same time, reproductive and developmental toxicity assessments use timed-pregnancy protocols to determine embryonic viability and teratogenic risk. Histopathological examinations and clinical chemistry analyses of tissue samples support regulatory submissions, and omics profiling (transcriptomics, proteomics, metabolomics) informs dose selection and mechanism-of-action studies. Service providers integrate these applications into end-to-end workflows for end users. Combined, these integrated applications ensure the dominance of drug discovery & development applications in the mice model market.

By region, North America accounted for the largest share of the mice model market in 2024.

In 2024, North America accounted for the largest share of the mice model market due to the concentration of major contract research organizations and breeding suppliers, government and private funding mechanisms, and a regulatory environment emphasizing standardized preclinical practices. The key market players, such as Charles River Laboratories (US), The Jackson Laboratory (US), and Inotiv (US), have their presence in the region, thus ensuring regional supply and technical support. Public funding agencies such as the National Institutes of Health (NIH) allocate substantial budgets to basic & translational research, while pharmaceutical & biotechnology companies commit a significant portion of R&D expenditure to preclinical in vivo models. Academic research institutions and specialized contract research organizations leverage this infrastructure and funding landscape to conduct target validation, toxicology, and efficacy studies, reinforcing North America’s large share in the global mice model market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives – 55%, Directors- 20%, and Others- 25%
• By Region: North America -45%, Europe – 20%, the Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan) Harbour BioMed (China), genOway (France), GemPharmatech (China), Cyagen (US), Ozgene Pty Ltd (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Vivo Bio Tech Ltd (India), ingenious targeting laboratory (US), Janvier Labs (France), Champions Oncology, Inc (US), and Vitalstar Biotechnology Co., Ltd. (China) are some of the key companies offering mice model products & services.

Research Coverage:

This research report categorizes the mice model market by model type & service [model types (inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice, breeding services, cryopreservation services, rederivation services, quarantine services, and other services)], by application (drug discovery & development, research applications, and personalized medicine), by technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies), by therapeutic area (oncology, neurology, immunology, metabolic diseases, cardiovascular diseases, and other therapeutic areas), by product end user (pharmaceutical & biotechnology companies, academic & research Institutes, and CROs & CDMOs), by services end user (pharmaceutical & biotechnology companies, government & biomedical research institutes, and CDMOs), and by region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report’s scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the mice model market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the mice model market. This report covers the competitive analysis of upcoming startups in the mice model market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the mice model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

• Analysis of key drivers (high adoption of mice models in preclinical studies, the increasing demand for mouse clinical trials, the rising demand for personalized medicine in oncology, technological advancements in genetic engineering), restrains (the introduction of 3D printed models, ethical concerns, and regulatory restrictions), opportunities (Utilization of CRISPR in biomedical research, and the rising demand for disease-specific models), and challenges (development of alternative animal testing methods and genetic & phenotypic variability).
• Product approvals: Detailed insights into newly approved products of the mice models market.
• Market development: Comprehensive information about lucrative markets – the report analyses the mice model market across varied regions.
• Market diversification: Exhaustive information about new products, recent developments, and investments in the mice model market.
• Pipeline analysis: Comprehensive information about products under clinical trials.
• Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), JSR Corporation (Japan), and Biocytogen (China).

Table of Contents

1               INTRODUCTION              40

1.1           STUDY OBJECTIVES       40

1.2           MARKET DEFINITION   40

1.3           MARKET SCOPE                41

1.3.1        INCLUSIONS & EXCLUSIONS       41

1.3.2        MARKETS & REGIONS COVERED               42

1.3.3        YEARS CONSIDERED      43

1.3.4        CURRENCY CONSIDERED            43

1.4           STAKEHOLDERS               43

1.5           SUMMARY OF CHANGES               44

2               RESEARCH METHODOLOGY       45

2.1           RESEARCH DATA              45

2.1.1        SECONDARY DATA          46

2.1.2        PRIMARY DATA 46

2.2           MARKET ESTIMATION METHODOLOGY               47

2.2.1        BOTTOM-UP APPROACH              48

2.2.2        INSIGHTS FROM PRIMARY EXPERTS        50

2.3           TOP-DOWN APPROACH                50

2.4           GROWTH FORECAST      52

2.5           MARKET BREAKDOWN AND DATA TRIANGULATION                 53

2.6           RESEARCH ASSUMPTIONS           54

2.7           LIMITATIONS    54

2.8           MARKET FORECAST       55

2.9           RISK ANALYSIS  55

3               EXECUTIVE SUMMARY  56

4               PREMIUM INSIGHTS       60

4.1           MICE MODEL MARKET OVERVIEW           60

4.2           NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE (2024)  61

4.3           MICE MODEL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              61

4.4           MICE MODEL MARKET, BY MODEL TYPE (END USER), 2025 VS. 2030       62

4.5           MICE MODEL MARKET SHARE, BY SERVICES (END USER)                 62

5               MARKET OVERVIEW       63

5.1           INTRODUCTION              63

5.2           MARKET DYNAMICS       63

5.2.1        DRIVERS               64

5.2.1.1    High adoption of mice models in preclinical studies      64

5.2.1.2    Increasing demand for Mouse Clinical Trials (MCTs)  65

5.2.1.3    Growing preference for personalized medicine in oncology                 66

5.2.1.4    Advancements in genetic engineering               67

5.2.2        RESTRAINTS      67

5.2.2.1    Introduction of 3D printed models   67

5.2.2.2    Ethical concerns and regulatory restrictions    68

5.2.3        OPPORTUNITIES              69

5.2.3.1    Utilization of CRISPR in biomedical research 69

5.2.3.2    Rising demand for disease-specific models      69

5.2.4        CHALLENGES    70

5.2.4.1    Development of alternative animal testing methods      70

5.2.4.2    Genetic & phenotypic variability        71

5.3           MICE MODEL MARKET LANDSCAPE        71

5.3.1        HISTORY OF MICE MODELS        71

5.3.2        MICE MODEL GENERATION PROCESS    72

5.3.3        TECHNIQUES FOR MICE MODEL DEVELOPMENT                 72

5.3.4        TECHNOLOGICAL ADVANCEMENTS      73

5.3.5        CONSIDERATIONS FOR MICE MODEL DEVELOPMENT                 74

5.4           VALUE CHAIN ANALYSIS               75

5.5           PRICING ANALYSIS          76

5.5.1        AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022−2024                 76

5.5.2       AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024        78

5.6           ECOSYSTEM ANALYSIS  79

5.6.1        MICE MODEL VENDORS                79

5.6.2        MICE MODEL SERVICE VENDORS             80

5.6.3        MICE MODEL END USERS             80

5.6.4        REGULATORY ORGANIZATIONS               81

5.7           TECHNOLOGY ANALYSIS             82

5.7.1        KEY TECHNOLOGIES     82

5.7.1.1    CRISPR/CAS9 gene editing               82

5.7.1.2    Pronuclear Microinjection (PNI)      82

5.7.1.3    Embryo cryopreservation & assisted reproduction          83

5.7.2        COMPLEMENTARY TECHNOLOGIES       83

5.7.2.1    Multimodal preclinical imaging          83

5.7.2.2    Automated behavioural phenotyping                 84

5.7.2.3    Integrated physiological monitoring  84

5.7.3        ADJACENT TECHNOLOGIES       84

5.7.3.1    Ex vivo CRISPR screening in cell culture         84

5.7.3.2    High-content bioinformatics pipeline               85

5.7.3.3    Mass spectroscopy-based tissue profiling         85

5.8           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       86

5.9           PATENT ANALYSIS          87

5.9.1        METHODOLOGY              87

5.9.2        PATENTS FILED, BY DOCUMENT TYPE, 2014−2024                 87

5.10         TRADE DATA ANALYSIS                89

5.10.1      IMPORT DATA  89

5.10.2      IMPORT DATA  90

5.11         KEY CONFERENCES & EVENTS   91

5.11.1      KEY CONFERENCES & EVENTS (2025–2026)            91

5.12         TARIFF & REGULATORY LANDSCAPE     92

5.12.1      TARIFF DATA (HS CODE 106.19.90)            92

5.12.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             93

5.12.3      REGULATORY FRAMEWORK       97

5.12.3.1  North America      97

5.12.3.2  Europe   98

5.12.3.3  China      100

5.12.3.4  Japan      100

5.12.3.5  India       101

5.12.3.6  Australia 102

5.12.3.7  Brazil      102

5.13         PORTER’S FIVE FORCES ANALYSIS           103

5.13.1      THREAT OF NEW ENTRANTS      104

5.13.2      THREAT OF SUBSTITUTES          104

5.13.3      BARGAINING POWER OF BUYERS             104

5.13.4      BARGAINING POWER OF SUPPLIERS       104

5.13.5      INTENSITY OF COMPETITIVE RIVALRY 104

5.14         KEY STAKEHOLDERS & BUYING CRITERIA            105

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           105

5.14.2      ROLE OF STAKEHOLDERS IN BUYING PROCESS 105

5.14.3      BUYING CRITERIA FOR MICE MODEL MARKET  106

5.15         INVESTMENT & FUNDING SCENARIO     107

5.16         IMPACT OF GENERATIVE AI ON MICE MODEL MARKET                 108

5.16.1      AI-USE CASES    108

5.16.2      KEY COMPANIES IMPLEMENTING AI      109

5.17         CASE STUDIES  109

5.17.1      CASE STUDY 1: AAV GENE EDITING IN CYAGEN LDLR MUTANT MICE AMELIORATES ATHEROSCLEROSIS          109

5.17.2      CASE STUDY 2: METABOLIC EFFECTS OF SEMAGLUTIDE & TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICEBAC                 109

5.17.3      CASE STUDY 3: TARGETING NATURAL KILLER CELL ACTIVITY WITH HUMANIZED NSG-IL15 MOUSE MODEL                 110

5.18         TRUMP TARIFF IMPACT ON MICE MODEL MARKET                 110

5.18.1      KEY TARIFF RATES          110

5.18.2      PRICE IMPACT ANALYSIS             112

5.18.3      KEY IMPACT ON VARIOUS REGIONS       112

5.18.3.1  US           112

5.18.3.2  Europe   112

5.18.3.3  Asia Pacific            113

5.18.3.4  Rest of the World 113

5.18.4      END-USE INDUSTRY IMPACT     113

5.18.4.1  Pharmaceutical & biotechnology companies    113

5.18.4.2  CROs & CDMOs 114

5.18.4.3  Academic & research institutes          114

6               MICE MODEL MARKET, BY MODEL TYPE & SERVICE                 115

6.1           INTRODUCTION              116

6.2           MODEL TYPE     116

6.2.1        INBRED MICE    119

6.2.1.1    High utilization across research applications to propel market                 119

6.2.2        GENETICALLY ENGINEERED MICE           122

6.2.2.1    Ability to induce mutations for CVD & cancer research to drive market    122

6.2.3        HYBRID/CONGENIC MICE            125

6.2.3.1    Growing focus on biomedical research to boost demand                 125

6.2.4        OUTBRED MICE                128

6.2.4.1    Genetic diversity benefits to support market growth      128

6.3           SERVICES             131

6.3.1        BREEDING SERVICES      134

6.3.1.1    Customization of models for specific research applications to boost demand        134

6.3.2        CRYOPRESERVATION SERVICES                137

6.3.2.1    Rising focus on preservation of novel mice models to propel market    137

6.3.3        REDERIVATION SERVICES            140

6.3.3.1    Stringent quality assurance standards to fuel market     140

6.3.4        QUARANTINE SERVICES                143

6.3.4.1    Rising demand for germ-free mice to support market growth                 143

6.3.5        OTHER SERVICES             146

7               MICE MODEL MARKET, BY TECHNOLOGY            150

7.1           INTRODUCTION              151

7.2           CRISPR/CAS9      151

7.2.1        ADVANTAGES SUCH AS SIMPLIFIED DESIGN AND COST EFFICIENCY TO PROPEL MARKET            151

7.3           MICROINJECTIONS         155

7.3.1        LOW TOXICITY AND HIGH SUCCESS RATE TO DRIVE MARKET               155

7.4           EMBRYONIC STEM CELL INJECTIONS    158

7.4.1        INCREASING DEMAND FOR TARGETED MICE MODELS IN IMMUNOLOGICAL RESEARCH TO FUEL MARKET        158

7.5           NUCLEAR TRANSFER TECHNIQUE           161

7.5.1        POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET               161

7.6           OTHER TECHNOLOGIES               164

8               MICE MODEL MARKET, BY APPLICATION             167

8.1           INTRODUCTION              168

8.2           DRUG DISCOVERY & DEVELOPMENT     168

8.2.1        INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET               168

8.3           RESEARCH APPLICATIONS          172

8.3.1        INCREASING FUNDING INVESTMENTS FOR CANCER RESEARCH TO DRIVE MARKET  172

8.4           PERSONALIZED MEDICINE          175

8.4.1        INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH             175

9               MICE MODEL MARKET, BY THERAPEUTIC AREA                 179

9.1           INTRODUCTION              180

9.2           ONCOLOGY        180

9.2.1        GROWING FOCUS ON THERAPEUTIC DEVELOPMENT TO PROPEL MARKET      180

9.3           METABOLIC DISEASES  184

9.3.1        INCREASING PREVALENCE OF ENDOCRINE DISORDERS TO DRIVE MARKET         184

9.4           IMMUNOLOGY 187

9.4.1        RISING CLINICAL RESEARCH ACTIVITIES FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET            187

9.5           NEUROLOGY     190

9.5.1        INCREASING INVESTMENTS IN R&D FOR CNS DISEASES TO BOOST DEMAND      190

9.6           CARDIOVASCULAR DISEASES    193

9.6.1        GROWING FOCUS ON TARGETED TREATMENTS FOR CVD TO BOOST DEMAND            193

9.7           OTHER THERAPEUTIC AREAS    196

10            MICE MODEL TYPE MARKET, BY END USER         200

10.1         INTRODUCTION              201

10.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 201

10.2.1      RISING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO FUEL MARKET          201

10.3         CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CROS & CDMOS)        205

10.3.1      INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE MARKET     205

10.4         ACADEMIC & RESEARCH INSTITUTES    208

10.4.1      INCREASING FUNDING INITIATIVES FOR LIFE SCIENCES R&D TO SUPPORT MARKET GROWTH    208

11            MICE MODEL SERVICES MARKET, BY END USER                 211

11.1         INTRODUCTION              212

11.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 212

11.2.1      RISING OUTSOURCING OF PRECLINICAL SERVICES TO PROPEL MARKET             212

11.3         CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)         215

11.3.1      DEVELOPMENT OF INTEGRATED MODELS AND GROWTH IN BIOLOGICS TO BOOST DEMAND   215

11.4         GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES                 218

11.4.1      FOCUS ON TRANSLATIONAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH     218

12            MICE MODEL MARKET, BY REGION         222

12.1         INTRODUCTION              223

12.2         NORTH AMERICA             223

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 223

12.2.2      US           228

12.2.2.1  Rising production of monoclonal antibodies to fuel market                 228

12.2.3      CANADA               232

12.2.3.1  Growth in stem cell research activities to fuel market    232

12.3         EUROPE               235

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      235

12.3.2      GERMANY           240

12.3.2.1  Growth in biotechnology industry to drive market         240

12.3.3      UK          243

12.3.3.1  Increasing focus on cancer research to propel market    243

12.3.4      FRANCE                246

12.3.4.1  Rising investments in proteomics & genomics research to boost demand  246

12.3.5      ITALY    249

12.3.5.1  Growth in pharmaceutical & biotechnology industry to drive market    249

12.3.6      SPAIN    252

12.3.6.1  Extensive R&D pipeline to fuel uptake             252

12.3.7      REST OF EUROPE             256

12.4         ASIA PACIFIC     259

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 259

12.4.2      CHINA  265

12.4.2.1  Favorable investments in life sciences research to drive market                 265

12.4.3      JAPAN   268

12.4.3.1  Increasing focus on personalized diagnostics products to drive market    268

12.4.4      INDIA    272

12.4.4.1  Favorable initiatives for drug discovery & development to boost market    272

12.4.5      AUSTRALIA         275

12.4.5.1  High number of research institutes to favor market growth                 275

12.4.6      SOUTH KOREA  278

12.4.6.1  Innovation in health & biotech sectors to support market uptake                 278

12.4.7      REST OF ASIA PACIFIC   281

12.5         LATIN AMERICA                285

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 285

12.5.2      BRAZIL 289

12.5.2.1  Increasing investments in biopharmaceutical research to fuel uptake    289

12.5.3      MEXICO                292

12.5.3.1  Expanding healthcare ecosystem to support market growth                 292

12.5.4      REST OF LATIN AMERICA             295

12.6         MIDDLE EAST   299

12.6.1      MACROECONOMIC OUTLOOK IN MIDDLE EAST                 299

12.6.2      GCC COUNTRIES              303

12.6.2.1  Kingdom of Saudi Arabia (KSA)        306

12.6.2.1.1                Growing focus on advancement of healthcare sector to boost market          306

12.6.2.2  United Arab Emirates          310

12.6.2.2.1                Increasing R&D activities and growing demand for personalized medicine to propel market           310

12.6.2.3  Other GCC Countries          314

12.6.3      REST OF MIDDLE EAST 317

12.7         AFRICA 321

12.7.1      RISING PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH     321

12.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        321

13            COMPETITIVE LANDSCAPE         325

13.1         OVERVIEW          325

13.2         KEY PLAYERS STRATEGIES/RIGHT TO WIN          325

13.2.1      STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022–2025         326

13.3         REVENUE SHARE ANALYSIS, 2022−2024  328

13.4         MARKET SHARE ANALYSIS           328

13.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 331

13.5.1      STARS   331

13.5.2      EMERGING LEADERS     331

13.5.3      PERVASIVE PLAYERS      331

13.5.4      PARTICIPANTS 331

13.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         333

13.5.5.1  Company footprint               333

13.5.5.2  Region footprint   334

13.5.5.3  Model type & service footprint           335

13.5.5.4  Application footprint            336

13.5.5.5  Technology footprint           337

13.5.5.6  Therapeutic area footprint  338

13.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        339

13.6.1      PROGRESSIVE COMPANIES         339

13.6.2      RESPONSIVE COMPANIES            339

13.6.3      DYNAMIC COMPANIES  339

13.6.4      STARTING BLOCKS         339

13.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 341

13.6.5.1  Detailed list of key startups/SME players         341

13.6.5.2  Competitive benchmarking of key startups/SMEs          342

13.7         COMPANY VALUATION & FINANCIAL METRICS 343

13.7.1      FINANCIAL METRICS      343

13.7.2      COMPANY VALUATION 343

13.8         BRAND/PRODUCT COMPARATIVE ANALYSIS     344

13.8.1      BRAND/PRODUCT COMPARATIVE ANALYSIS FOR MICE MODEL MARKET              344

13.9         COMPETITIVE SCENARIO             345

13.9.1      PRODUCT/SERVICE LAUNCHES                 345

13.9.2      DEALS  345

13.9.3      EXPANSIONS     349

13.9.4      OTHER DEVELOPMENTS              351

14            COMPANY PROFILES      352

14.1         KEY PLAYERS     352

14.1.1      CHARLES RIVER LABORATORIES               352

14.1.1.1  Business overview 352

14.1.1.2  Products/Services offered   353

14.1.1.3  Recent developments           356

14.1.1.3.1                Deals      356

14.1.1.3.2                Expansions             357

14.1.1.3.3                Other developments             358

14.1.1.4  MnM view              358

14.1.1.4.1                Key strengths        358

14.1.1.4.2                Strategic choices   358

14.1.1.4.3                Weaknesses & competitive threats     358

14.1.2      THE JACKSON LABORATORY      359

14.1.2.1  Business overview 359

14.1.2.2  Products/Services offered   360

14.1.2.3  Recent developments           366

14.1.2.3.1                Deals      366

14.1.2.3.2                Expansions             367

14.1.2.4  MnM view              368

14.1.2.4.1                Key strengths        368

14.1.2.4.2                Strategic choices   368

14.1.2.4.3                Weaknesses & competitive threats     368

14.1.3      INOTIV 369

14.1.3.1  Business overview 369

14.1.3.2  Products/Services offered   370

14.1.3.3  Recent developments           373

14.1.3.3.1                Deals      373

14.1.3.3.2                Expansions             374

14.1.3.4  MnM view              374

14.1.3.4.1                Key strengths        374

14.1.3.4.2                Strategic choices   374

14.1.3.4.3                Weaknesses & competitive threats     374

14.1.4      JSR CORPORATION         375

14.1.4.1  Business overview 375

14.1.4.2  Product/Services offered     376

14.1.4.3  Recent developments           378

14.1.4.3.1                Deals      378

14.1.4.3.2                Expansions             378

14.1.4.4  MnM view              379

14.1.4.4.1                Key strengths        379

14.1.4.4.2                Strategic choices   379

14.1.4.4.3                Weaknesses & competitive threats     379

14.1.5      BIOCYTOGEN   380

14.1.5.1  Business overview 380

14.1.5.2  Product/Services offered     381

14.1.5.3  Recent developments           383

14.1.5.3.1                Product/Service launches   383

14.1.5.3.2                Deals      383

14.1.5.3.3                Expansions             385

14.1.5.4  MnM view              385

14.1.5.4.1                Key strengths        385

14.1.5.4.2                Strategic choices   385

14.1.5.4.3                Weaknesses & competitive threats     386

14.1.6      SHANGHAI MODEL ORGANISMS CENTER, INC.  387

14.1.6.1  Business overview 387

14.1.6.2  Product/Services offered     388

14.1.6.3  Recent developments           389

14.1.6.3.1                Deals      389

14.1.7      TRANS GENIC INC.          390

14.1.7.1  Business overview 390

14.1.7.2  Products/Services offered   391

14.1.7.3  Recent developments           392

14.1.7.3.1                Deals      392

14.1.8      HARBOUR BIOMED         393

14.1.8.1  Business overview 393

14.1.8.2  Product/Services offered     394

14.1.8.3  Recent developments           395

14.1.8.3.1                Deals      395

14.1.8.3.2                Other developments             397

14.1.9      GENOWAY          398

14.1.9.1  Business overview 398

14.1.9.2  Product/Services offered     399

14.1.9.3  Recent developments           401

14.1.9.3.1                Deals      401

14.1.10   GEMPHARMATECH         402

14.1.10.1                 Business overview 402

14.1.10.2                 Product/Services offered     403

14.1.10.3                 Recent developments           404

14.1.10.3.1             Product/Service launches   404

14.1.10.3.2             Deals      405

14.1.10.3.3             Expansions             405

14.1.11   CYAGEN               406

14.1.11.1                 Business overview 406

14.1.11.2                 Product/Services offered     406

14.1.11.3                 Recent developments           407

14.1.11.3.1             Deals      407

14.1.12   OZGENE PTY LTD.           408

14.1.12.1                 Business overview 408

14.1.12.2                 Products/Services offered   408

14.1.12.3                 Recent developments           409

14.1.12.3.1             Deals      409

14.1.13   TACONIC BIOSCIENCES, INC.     410

14.1.13.1                 Business overview 410

14.1.13.2                 Products/Services offered   410

14.1.13.3                 Recent developments           412

14.1.13.3.1             Product/Service launches   412

14.1.13.3.2             Deals      413

14.1.13.3.3             Expansions             413

14.1.14   TRANSCURE BIOSERVICES          414

14.1.14.1                 Business overview 414

14.1.14.2                 Products/Services offered   414

14.1.14.3                 Recent developments           415

14.1.14.3.1             Deals      415

14.1.15   VIVO BIO TECH LTD.     416

14.1.15.1                 Business overview 416

14.1.15.2                 Product/Services offered     417

14.1.16   INGENIOUS TARGETING LABORATORY 418

14.1.16.1                 Business overview 418

14.1.16.2                 Product/Services offered     418

14.1.17   JANVIER LABS    420

14.1.17.1                 Business overview 420

14.1.17.2                 Product/Services offered     420

14.1.17.3                 Recent developments           423

14.1.17.3.1             Deals      423

14.1.18   CHAMPIONS ONCOLOGY, INC.  424

14.1.18.1                 Business overview 424

14.1.18.2                 Products offered   425

14.1.18.3                 Recent developments           425

14.1.18.3.1             Deals      425

14.1.19   VITALSTAR BIOTECHNOLOGY CO., LTD.              426

14.1.19.1                 Business overview 426

14.1.19.2                 Products offered   426

14.2         OTHER PLAYERS              427

14.2.1      ONCODESIGN SERVICES               427

14.2.2      CLEA JAPAN, INC.             428

14.2.3      APPLIED STEMCELL       429

14.2.4      CREATIVE ANIMODEL   430

14.2.5      JOINN LABORATORIES (CHINA) CO., LTD.            431

14.2.6      CREATIVE BIOLABS        432

14.2.7      CRESCENDO BIOLOGICS LIMITED           433

14.2.8      ARAGEN LIFE SCIENCES LTD.     434

14.2.9      POLYGENE         435

14.2.10   PHARMTEST SERVICES 436

14.2.11   MARSHALL BIORESOURCES        437

15            APPENDIX           438

15.1         DISCUSSION GUIDE        438

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                442

15.3         CUSTOMIZATION OPTIONS        444

15.4         RELATED REPORTS         444

15.5         AUTHOR DETAILS           445

LIST OF TABLES

TABLE 1                MICE MODEL MARKET: IMPACT ANALYSIS                 55

TABLE 2                MICE MODEL MARKET: RISK ASSESSMENT ANALYSIS            55

TABLE 3                MICE MODEL MARKET: IMPACT ANALYSIS                 64

TABLE 4                AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER, 20222−2024         76

TABLE 5                AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION, 2024     78

TABLE 6                MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY VENDORS     80

TABLE 7                MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY SERVICE VENDOR     80

TABLE 8                MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY END USER     81

TABLE 9                MICE MODEL MARKET: ROLE IN ECOSYSTEM, BY REGULATORY ORGANIZATION           81

TABLE 10              PATENTS FILED, BY DOCUMENT TYPE, 2014−2024            87

TABLE 11              PATENTS IN MICE MODELS MARKET      89

TABLE 12              IMPORT VALUE OF HS CODE 106.19.90–COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020−2024 (USD THOUSANDS)        89

TABLE 13              IMPORT VALUE OF HS CODE 106.19.90−COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020−2024 (USD THOUSANDS)  90

TABLE 14              MICE MODEL MARKET: CONFERENCES & EVENTS (2025–2026)         91

TABLE 15              NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             93

TABLE 16              EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 93

TABLE 17              ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 94

TABLE 18              REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             95

TABLE 19              MICE MODEL MARKET: REGULATORY SCENARIO           95

TABLE 20              MICE MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS            103

TABLE 21              INVESTMENT & FUNDING ACTIVITIES, BY KEY PLAYER, 2022−2025          107

TABLE 22              US-ADJUSTED RECIPROCAL TARIFF RATES                 110

TABLE 23              KEY PRODUCT-RELATED TARIFFS: LIVE ANIMALS, PRODUCT OF ANIMAL ORIGIN, AND MISCELLANEOUS CHEMICAL PRODUCTS             111

TABLE 24              CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES            112

TABLE 25              MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)         116

TABLE 26              MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 116

TABLE 27              NORTH AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            117

TABLE 28              EUROPE: MICE MODEL TYPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     117

TABLE 29              ASIA PACIFIC: MICE MODEL TYPE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            117

TABLE 30              LATIN AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            118

TABLE 31              MIDDLE EAST: MICE MODEL TYPE MARKET, BY REGION,

2023–2030 (USD MILLION)            118

TABLE 32              GCC COUNTRIES: MICE MODEL TYPE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            118

TABLE 33              MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            119

TABLE 34              INBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)            120

TABLE 35              NORTH AMERICA: INBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 36              EUROPE: INBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 37              ASIA PACIFIC: INBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            121

TABLE 38              LATIN AMERICA: INBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            121

TABLE 39              MIDDLE EAST: INBRED MICE MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            121

TABLE 40              GCC COUNTRIES: INBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            122

TABLE 41              GENETICALLY ENGINEERED MICE MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            123

TABLE 42              NORTH AMERICA: GENETICALLY ENGINEERED MICE MODEL MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               123

TABLE 43              EUROPE: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            123

TABLE 44              ASIA PACIFIC: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 124

TABLE 45              LATIN AMERICA: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 124

TABLE 46              MIDDLE EAST: GENETICALLY ENGINEERED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)                 124

TABLE 47              GCC COUNTRIES: GENETICALLY ENGINEERED MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 125

TABLE 48              HYBRID/CONGENIC MICE MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            126

TABLE 49              NORTH AMERICA: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 50              EUROPE: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 51              ASIA PACIFIC: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 52              LATIN AMERICA: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 53              MIDDLE EAST: HYBRID/CONGENIC MICE MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            127

TABLE 54              GCC COUNTRIES: HYBRID/CONGENIC MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            128

TABLE 55              OUTBRED MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)            128

TABLE 56              NORTH AMERICA: OUTBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 57              EUROPE: OUTBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 58             ASIA PACIFIC: OUTBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 59              LATIN AMERICA: OUTBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 60              MIDDLE EAST: OUTBRED MICE MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            130

TABLE 61              GCC COUNTRIES: OUTBRED MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 62              MICE MODEL SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            131

TABLE 63              NORTH AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            131

TABLE 64              EUROPE: MICE MODEL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 65              ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 66              LATIN AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 67             MIDDLE EAST: MICE MODEL SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            133

TABLE 68              GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            133

TABLE 69              MICE MODEL SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            133

TABLE 70              MICE MODEL BREEDING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 71              NORTH AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 135

TABLE 72              EUROPE: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 73              ASIA PACIFIC: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            135

TABLE 74              LATIN AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 75              MIDDLE EAST: MICE MODEL BREEDING SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            136

TABLE 76              GCC COUNTRIES: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 136

TABLE 77              MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            137

TABLE 78              NORTH AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               138

TABLE 79              EUROPE: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 80              ASIA PACIFIC: MICE MODEL CRYOPRESERVATION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 81              LATIN AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               139

TABLE 82              MIDDLE EAST: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION 2023–2030 (USD MILLION) 139

TABLE 83              GCC COUNTRIES: MICE MODEL CRYOPRESERVATION SERVICES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               140

TABLE 84              MICE MODEL REDERIVATION SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            141

TABLE 85              NORTH AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141

TABLE 86              EUROPE: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 87              ASIA PACIFIC: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 142

TABLE 88              LATIN AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 142

TABLE 89              MIDDLE EAST: MICE MODEL REDERIVATION SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 90              GCC COUNTRIES: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 143

TABLE 91              MICE MODEL QUARANTINE SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            144

TABLE 92              NORTH AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 144

TABLE 93              EUROPE: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 94              ASIA PACIFIC: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 95              LATIN AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 145

TABLE 96              MIDDLE EAST: MICE MODEL QUARANTINE SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            145

TABLE 97              GCC COUNTRIES: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 146

TABLE 98              MICE MODEL MARKET FOR OTHER SERVICES, BY REGION,

2023–2030 (USD MILLION)            147

TABLE 99              NORTH AMERICA: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 147

TABLE 100            EUROPE: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 101            ASIA PACIFIC: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 102            LATIN AMERICA: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 148

TABLE 103            MIDDLE EAST: MICE MODEL MARKET FOR OTHER SERVICES, BY REGION,

2023–2030 (USD MILLION)            148

TABLE 104            GCC COUNTRIES: MICE MODEL MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 149

TABLE 105            MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)       151

TABLE 106            MICE MODEL MARKET FOR CRISPR/CAS9, BY REGION,

2023–2030 (USD MILLION)            152

TABLE 107            NORTH AMERICA: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 108            EUROPE: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 109            ASIA PACIFIC: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 110            LATIN AMERICA: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 111            MIDDLE EAST: MICE MODEL MARKET FOR CRISPR/CAS9, BY REGION,

2023–2030 (USD MILLION)            154

TABLE 112            GCC COUNTRIES: MICE MODEL MARKET FOR CRISPR/CAS9, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 113            MICE MODEL MARKET FOR MICROINJECTIONS, BY REGION,

2023–2030 (USD MILLION)            155

TABLE 114            NORTH AMERICA: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 156

TABLE 115            EUROPE: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 116            ASIA PACIFIC: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 117            LATIN AMERICA: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 157

TABLE 118            MIDDLE EAST: MICE MODEL MARKET FOR MICROINJECTIONS, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 119            GCC COUNTRIES: MICE MODEL MARKET FOR MICROINJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 157

TABLE 120            MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY REGION, 2023–2030 (USD MILLION)                 158

TABLE 121            NORTH AMERICA: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159

TABLE 122            EUROPE: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 123            ASIA PACIFIC: MICE MODEL MARKET FOR EMBRYONIC STEM CELL INJECTIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 124            LATIN AMERICA: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 125            MIDDLE EAST: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY REGION, 2023–2030 (USD MILLION) 160

TABLE 126            GCC COUNTRIES: MICE MODELS MARKET FOR EMBRYONIC STEM CELL INJECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 160

TABLE 127            MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE, BY REGION,

2023–2030 (USD MILLION)          161

TABLE 128            NORTH AMERICA: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 129            EUROPE: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 130            ASIA PACIFIC: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 131            LATIN AMERICA: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 132            MIDDLE EAST: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY REGION, 2023–2030 (USD MILLION)   163

TABLE 133            GCC COUNTRIES: MICE MODEL MARKET FOR NUCLEAR TRANSFER TECHNIQUE,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 134            MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION,

2023–2030 (USD MILLION)            164

TABLE 135            NORTH AMERICA: MICE MODEL MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION)               165

TABLE 136            EUROPE: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 137            ASIA PACIFIC: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)            165

TABLE 138            LATIN AMERICA: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)            166

TABLE 139            MIDDLE EAST: MICE MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)                 166

TABLE 140            GCC COUNTRIES: MICE MODEL MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION)               166

TABLE 141            MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       168

TABLE 142            MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 169

TABLE 143            NORTH AMERICA: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 169

TABLE 144            EUROPE: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               170

TABLE 145            ASIA PACIFIC: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               170

TABLE 146            LATIN AMERICA: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 171

TABLE 147            MIDDLE EAST: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT,

BY REGION, 2023–2030 (USD MILLION)   171

TABLE 148            GCC COUNTRIES: MICE MODEL MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 171

TABLE 149            MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY REGION,

2023–2030 (USD MILLION)            173

TABLE 150            NORTH AMERICA: MICE MODEL MARKET FOR RESEARCH APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               173

TABLE 151            EUROPE: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)                 173

TABLE 152            ASIA PACIFIC: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            174

TABLE 153            LATIN AMERICA: MICE MODEL MARKET FOR RESEARCH APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               174

TABLE 154            MIDDLE EAST: MICE MODEL MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)            174

TABLE 155            GCC COUNTRIES: MICE MODEL MARKET FOR RESEARCH APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               175

TABLE 156            MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY REGION,

2023–2030 (USD MILLION)            176

TABLE 157            NORTH AMERICA: MICE MODEL MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2023–2030 (USD MILLION)               176

TABLE 158            EUROPE: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)            176

TABLE 159            ASIA PACIFIC: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)            177

TABLE 160            LATIN AMERICA: MICE MODEL MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2023–2030 (USD MILLION)               177

TABLE 161            MIDDLE EAST: MICE MODEL MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION)            177

TABLE 162            GCC COUNTRIES: MICE MODEL MARKET FOR PERSONALIZED MEDICINE,

BY COUNTRY, 2023–2030 (USD MILLION)               178

TABLE 163            MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            180

TABLE 164            MICE MODEL MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)          181

TABLE 165            NORTH AMERICA: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            181

TABLE 166            EUROPE: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 167            ASIA PACIFIC: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 168            LATIN AMERICA: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 169            MIDDLE EAST: MICE MODEL MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)            183

TABLE 170            GCC COUNTRIES: MICE MODEL MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 171            MICE MODEL MARKET FOR METABOLIC DISEASES, BY REGION,

2023–2030 (USD MILLION)            184

TABLE 172            NORTH AMERICA: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 185

TABLE 173            EUROPE: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY,

2023–2030 (USD MILLION)            185

TABLE 174            ASIA PACIFIC: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 185

TABLE 175            LATIN AMERICA: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 186

TABLE 176            MIDDLE EAST: MICE MODEL MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION)                 186

TABLE 177            GCC COUNTRIES: MICE MODEL MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 186

TABLE 178            MICE MODEL MARKET FOR IMMUNOLOGY, BY REGION,

2023–2030 (USD MILLION)            187

TABLE 179            NORTH AMERICA: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 180            EUROPE: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 181            ASIA PACIFIC: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 182            LATIN AMERICA: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            189

TABLE 183            MIDDLE EAST: MICE MODEL MARKET FOR IMMUNOLOGY, BY REGION,

2023–2030 (USD MILLION)            189

TABLE 184            GCC COUNTRIES: MICE MODEL MARKET FOR IMMUNOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            189

TABLE 185            MICE MODEL MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION)          190

TABLE 186            NORTH AMERICA: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            191

TABLE 187            EUROPE: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            191

TABLE 188            ASIA PACIFIC: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            191

TABLE 189            LATIN AMERICA: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            192

TABLE 190            MIDDLE EAST: MICE MODEL MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)            192

TABLE 191            GCC COUNTRIES: MICE MODEL MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            192

TABLE 192            MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,

2023–2030 (USD MILLION)            193

TABLE 193            NORTH AMERICA: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 194            EUROPE: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            194

TABLE 195            ASIA PACIFIC: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 196            LATIN AMERICA: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 197            MIDDLE EAST: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES,

BY REGION, 2023–2030 (USD MILLION)   195

TABLE 198            GCC COUNTRIES: MICE MODEL MARKET FOR CARDIOVASCULAR DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               195

TABLE 199            MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,

2023–2030 (USD MILLION)            197

TABLE 200            NORTH AMERICA: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               197

TABLE 201            EUROPE: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 202            ASIA PACIFIC: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 203            LATIN AMERICA: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 204            MIDDLE EAST: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2023–2030 (USD MILLION)   198

TABLE 205            GCC COUNTRIES: MICE MODEL MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               199

TABLE 206            MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)            201

TABLE 207            MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          202

TABLE 208            NORTH AMERICA: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     202

TABLE 209            EUROPE: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     203

TABLE 210            ASIA PACIFIC: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     203

TABLE 211            LATIN AMERICA: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     204

TABLE 212            MIDDLE EAST: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          204

TABLE 213            GCC COUNTRIES: MICE MODEL TYPE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     204

TABLE 214            MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY REGION,

2023–2030 (USD MILLION)            205

TABLE 215            NORTH AMERICA: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)                 206

TABLE 216            EUROPE: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY,

2023–2030 (USD MILLION)            206

TABLE 217            ASIA PACIFIC: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)                 206

TABLE 218            LATIN AMERICA: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 USD MILLION)                 207

TABLE 219            MIDDLE EAST: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 207

TABLE 220            GCC COUNTRIES: MICE MODEL TYPE MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)                 207

TABLE 221            MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)                 208

TABLE 222            NORTH AMERICA: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       209

TABLE 223            EUROPE: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209

TABLE 224            ASIA PACIFIC: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 209

TABLE 225            LATIN AMERICA: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       210

TABLE 226            MIDDLE EAST: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 210

TABLE 227            GCC COUNTRIES: MICE MODEL TYPE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)       210

TABLE 228            MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            212

TABLE 229            MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          213

TABLE 230            NORTH AMERICA: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   213

TABLE 231            EUROPE: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     213

TABLE 232            ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)     214

TABLE 233            LATIN AMERICA: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   214

TABLE 234            MIDDLE EAST: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          214

TABLE 235            GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   215

TABLE 236            MICE MODEL SERVICES MARKET FOR CDMOS, BY REGION,

2023–2030 (USD MILLION)            216

TABLE 237            NORTH AMERICA: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)                 216

TABLE 238            EUROPE: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY,

2023–2030 (USD MILLION)            216

TABLE 239            ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY,

2023–2030 (USD MILLION)            217

TABLE 240            LATIN AMERICA: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 USD MILLION)                 217

TABLE 241            MIDDLE EAST: MICE MODEL SERVICES MARKET FOR CDMOS, BY REGION,

2023–2030 (USD MILLION)            217

TABLE 242            GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)                 218

TABLE 243            MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)          219

TABLE 244            NORTH AMERICA: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)   219

TABLE 245            EUROPE: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     219

TABLE 246            ASIA PACIFIC: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     220

TABLE 247            LATIN AMERICA: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)   220

TABLE 248            MIDDLE EAST: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)          220

TABLE 249            GCC COUNTRIES: MICE MODEL SERVICES MARKET FOR GOVERNMENT & BIOMEDICAL RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)   221

TABLE 250            MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 223

TABLE 251            NORTH AMERICA: MACROECONOMIC INDICATORS      224

TABLE 252            NORTH AMERICA: MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            225

TABLE 253            NORTH AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            226

TABLE 254            NORTH AMERICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)                226

TABLE 255            NORTH AMERICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         226

TABLE 256            NORTH AMERICA: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            227

TABLE 257            NORTH AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            227

TABLE 258            NORTH AMERICA: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            227

TABLE 259            NORTH AMERICA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            228

TABLE 260            NORTH AMERICA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              228

TABLE 261            US: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            229

TABLE 262            US: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 230

TABLE 263            US: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)       230

TABLE 264            US: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            230

TABLE 265            US: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               231

TABLE 266            US: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            231

TABLE 267            US: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)            231

TABLE 268            US: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 232

TABLE 269            CANADA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            233

TABLE 270            CANADA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       233

TABLE 271            CANADA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            233

TABLE 272            CANADA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            234

TABLE 273            CANADA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            234

TABLE 274            CANADA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              234

TABLE 275            CANADA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                235

TABLE 276            CANADA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              235

TABLE 277            EUROPE: MACROECONOMIC INDICATORS                 236

TABLE 278            EUROPE: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            237

TABLE 279            EUROPE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            237

TABLE 280            EUROPE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       237

TABLE 281            EUROPE: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            238

TABLE 282            EUROPE: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            238

TABLE 283            EUROPE: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            238

TABLE 284            EUROPE: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              239

TABLE 285            EUROPE: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                239

TABLE 286            EUROPE: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              239

TABLE 287            GERMANY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            240

TABLE 288            GERMANY: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            241

TABLE 289            GERMANY: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            241

TABLE 290            GERMANY: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            241

TABLE 291            GERMANY: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            242

TABLE 292            GERMANY: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              242

TABLE 293            GERMANY: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            242

TABLE 294            GERMANY: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              243

TABLE 295            UK: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            243

TABLE 296            UK: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION) 244

TABLE 297            UK: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)       244

TABLE 298            UK: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            244

TABLE 299            UK: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               245

TABLE 300            UK: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            245

TABLE 301            UK: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)            245

TABLE 302            UK: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION 246

TABLE 303            FRANCE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            246

TABLE 304            FRANCE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       247

TABLE 305            FRANCE: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            247

TABLE 306            FRANCE: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            247

TABLE 307            FRANCE: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            248

TABLE 308            FRANCE: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              248

TABLE 309            FRANCE: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                248

TABLE 310            FRANCE: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              249

TABLE 311            ITALY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            250

TABLE 312            ITALY: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       250

TABLE 313            ITALY: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            250

TABLE 314            ITALY: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            251

TABLE 315            ITALY: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                251

TABLE 316          ITALY: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            251

TABLE 317            ITALY: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                252

TABLE 318            ITALY: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION       252

TABLE 319            SPAIN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            253

TABLE 320            SPAIN: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       253

TABLE 321            SPAIN: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            254

TABLE 322            SPAIN: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            254

TABLE 323            SPAIN: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                254

TABLE 324          SPAIN: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            255

TABLE 325            SPAIN: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                255

TABLE 326            SPAIN: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              255

TABLE 327            REST OF EUROPE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            256

TABLE 328            REST OF EUROPE: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)                257

TABLE 329            REST OF EUROPE: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            257

TABLE 330            REST OF EUROPE: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            257

TABLE 331            REST OF EUROPE: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            258

TABLE 332            REST OF EUROPE: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            258

TABLE 333            REST OF EUROPE: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            258

TABLE 334            REST OF EUROPE: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              259

TABLE 335            ASIA PACIFIC: MACROECONOMIC INDICATORS                 260

TABLE 336            ASIA PACIFIC: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     262

TABLE 337            ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            262

TABLE 338            ASIA PACIFIC: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            262

TABLE 339            ASIA PACIFIC: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         263

TABLE 340            ASIA PACIFIC: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            263

TABLE 341            ASIA PACIFIC: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            264

TABLE 342            ASIA PACIFIC: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              264

TABLE 343            ASIA PACIFIC: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            264

TABLE 344            ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              265

TABLE 345            CHINA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            266

TABLE 346            CHINA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       266

TABLE 347            CHINA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            266

TABLE 348            CHINA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            267

TABLE 349            CHINA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            267

TABLE 350            CHINA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              267

TABLE 351            CHINA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                268

TABLE 352            CHINA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              268

TABLE 353            JAPAN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            269

TABLE 354            JAPAN: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       269

TABLE 355            JAPAN: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            270

TABLE 356            JAPAN: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            270

TABLE 357            JAPAN: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            270

TABLE 358            JAPAN: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              271

TABLE 359            JAPAN: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                271

TABLE 360            JAPAN: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              271

TABLE 361            INDIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            272

TABLE 362            INDIA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       273

TABLE 363            INDIA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            273

TABLE 364            INDIA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            273

TABLE 365            INDIA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                274

TABLE 366          INDIA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            274

TABLE 367            INDIA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                274

TABLE 368            INDIA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION       275

TABLE 369            AUSTRALIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            276

TABLE 370            AUSTRALIA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            276

TABLE 371          AUSTRALIA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            276

TABLE 372            AUSTRALIA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            277

TABLE 373            AUSTRALIA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            277

TABLE 374            AUSTRALIA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              277

TABLE 375            AUSTRALIA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            278

TABLE 376            AUSTRALIA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              278

TABLE 377            SOUTH KOREA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            279

TABLE 378          SOUTH KOREA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            279

TABLE 379            SOUTH KOREA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         279

TABLE 380            SOUTH KOREA: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            280

TABLE 381            SOUTH KOREA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            280

TABLE 382            SOUTH KOREA: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            280

TABLE 383            SOUTH KOREA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            281

TABLE 384            SOUTH KOREA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              281

TABLE 385            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            282

TABLE 386            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            282

TABLE 387            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            283

TABLE 388            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            283

TABLE 389            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            284

TABLE 390            REST OF ASIA PACIFIC: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            284

TABLE 391            REST OF ASIA PACIFIC: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            284

TABLE 392            REST OF ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              285

TABLE 393            LATIN AMERICA: MACROECONOMIC INDICATORS      286

TABLE 394            LATIN AMERICA: MICE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     286

TABLE 395            LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            286

TABLE 396            LATIN AMERICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)                287

TABLE 397            LATIN AMERICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         287

TABLE 398            LATIN AMERICA: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            287

TABLE 399            LATIN AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            288

TABLE 400            LATIN AMERICA: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            288

TABLE 401            LATIN AMERICA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            288

TABLE 402            LATIN AMERICA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              289

TABLE 403            BRAZIL: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            290

TABLE 404            BRAZIL: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       290

TABLE 405            BRAZIL: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            290

TABLE 406            BRAZIL: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            291

TABLE 407            BRAZIL: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            291

TABLE 408            BRAZIL: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              291

TABLE 409            BRAZIL: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                292

TABLE 410            BRAZIL: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              292

TABLE 411            MEXICO: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            293

TABLE 412            MEXICO: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       293

TABLE 413            MEXICO: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            293

TABLE 414            MEXICO: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            294

TABLE 415            MEXICO: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            294

TABLE 416            MEXICO: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              294

TABLE 417            MEXICO: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                295

TABLE 418            MEXICO: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION              295

TABLE 419            REST OF LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)                 296

TABLE 420            REST OF LATIN AMERICA: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            296

TABLE 421            REST OF LATIN AMERICA: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            297

TABLE 422            REST OF LATIN AMERICA: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            297

TABLE 423            REST OF LATIN AMERICA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            298

TABLE 424            REST OF LATIN AMERICA: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            298

TABLE 425            REST OF LATIN AMERICA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            298

TABLE 426            REST OF LATIN AMERICA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            299

TABLE 427            MIDDLE EAST: MACROECONOMIC INDICATORS                 300

TABLE 428            MIDDLE EAST: MICE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)          300

TABLE 429            MIDDLE EAST: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            300

TABLE 430            MIDDLE EAST: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)            301

TABLE 431            MIDDLE EAST: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         301

TABLE 432            MIDDLE EAST: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            301

TABLE 433            MIDDLE EAST: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            302

TABLE 434            MIDDLE EAST: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            302

TABLE 435            MIDDLE EAST: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            302

TABLE 436          MIDDLE EAST: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            303

TABLE 437            GCC COUNTRIES: MICE MODEL MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            303

TABLE 438            GCC COUNTRIES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            304

TABLE 439            GCC COUNTRIES: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)                304

TABLE 440            GCC COUNTRIES: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)         304

TABLE 441            GCC COUNTRIES: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            305

TABLE 442            GCC COUNTRIES: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            305

TABLE 443            GCC COUNTRIES: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            305

TABLE 444            GCC COUNTRIES: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            306

TABLE 445            GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            306

TABLE 446            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)                 307

TABLE 447            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            307

TABLE 448            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            308

TABLE 449            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            308

TABLE 450            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 309

TABLE 451            KINGDOM OF SAUDI ARABIA: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            309

TABLE 452            KINGDOM OF SAUDI ARABIA: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            309

TABLE 453            KINGDOM OF SAUDI ARABIA: MICE MODEL SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 310

TABLE 454            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)                 311

TABLE 455            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            311

TABLE 456            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            311

TABLE 457            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            312

TABLE 458            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            312

TABLE 459            UNITED ARAB EMIRATES: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            313

TABLE 460            UNITED ARAB EMIRATES: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            313

TABLE 461            UNITED ARAB EMIRATES: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            313

TABLE 462            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)                 314

TABLE 463            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            315

TABLE 464            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            315

TABLE 465            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            315

TABLE 466            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            316

TABLE 467            OTHER GCC COUNTRIES: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            316

TABLE 468            OTHER GCC COUNTRIES: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            316

TABLE 469            OTHER GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            317

TABLE 470            REST OF MIDDLE EAST: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 318

TABLE 471            REST OF MIDDLE EAST: MICE MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 472            REST OF MIDDLE EAST: MICE MODEL MARKET, BY SERVICE,

2023–2030 (USD MILLION)            318

TABLE 473            REST OF MIDDLE EAST: MICE MODEL MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION)            319

TABLE 474            REST OF MIDDLE EAST: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            319

TABLE 475            REST OF MIDDLE EAST: MICE MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            320

TABLE 476            REST OF MIDDLE EAST: MICE MODEL TYPE MARKET, BY END USER,

2023–2030 (USD MILLION)            320

TABLE 477            REST OF MIDDLE EAST: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            320

TABLE 478            MACROECONOMIC OUTLOOK FOR AFRICA                 322

TABLE 479            AFRICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2023–2030 (USD MILLION)            322

TABLE 480            AFRICA: MICE MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)       322

TABLE 481            AFRICA: MICE MODEL MARKET, BY SERVICE, 2023–2030 (USD MILLION)            323

TABLE 482            AFRICA: MICE MODEL MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)            323

TABLE 483            AFRICA: MICE MODEL MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            323

TABLE 484            AFRICA: MICE MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              324

TABLE 485            AFRICA: MICE MODEL TYPE MARKET, BY END USER, 2023–2030 (USD MILLION)                324

TABLE 486            AFRICA: MICE MODEL SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            324

TABLE 487            STRATEGIES ADOPTED BY KEY PLAYERS IN MICE MODEL MARKET, 2022−2025           326

TABLE 488            MICE MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY                 329

TABLE 489            MICE MODEL MARKET: REGION FOOTPRINT                 334

TABLE 490            MICE MODEL MARKET: MODEL TYPE & SERVICE FOOTPRINT       335

TABLE 491            MICE MODEL MARKET: APPLICATION FOOTPRINT       336

TABLE 492            MICE MODEL MARKET: TECHNOLOGY FOOTPRINT       337

TABLE 493            MICE MODEL MARKET: THERAPEUTIC AREA FOOTPRINT       338

TABLE 494            MICE MODEL MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS             341

TABLE 495            MICE MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          342

TABLE 496            MICE MODEL MARKET: PRODUCT/SERVICE LAUNCHES,

JANUARY 2022−JUNE 2025            345

TABLE 497            MICE MODEL MARKET: DEALS, JANUARY 2022−JUNE 2025                345

TABLE 498            MICE MODEL MARKET: EXPANSIONS, JANUARY 2022−JUNE 2025                349

TABLE 499            MICE MODEL MARKET: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025       351

TABLE 500            CHARLES RIVER LABORATORIES: COMPANY OVERVIEW          352

TABLE 501            CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED               353

TABLE 502            CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022−JUNE 2025            356

TABLE 503            CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022−JUNE 2025            357

TABLE 504            CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS,

JANUARY 2022−JUNE 2025            358

TABLE 505            THE JACKSON LABORATORY: COMPANY OVERVIEW          359

TABLE 506            THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED               360

TABLE 507            THE JACKSON LABORATORY: DEALS, JANUARY 2022−JUNE 2025                366

TABLE 508            THE JACKSON LABORATORY: EXPANSIONS, JANUARY 2022−JUNE 2025            367

TABLE 509            INOTIV: COMPANY OVERVIEW 369

TABLE 510            INOTIV: PRODUCTS/SERVICES OFFERED                 370

TABLE 511            INOTIV: DEALS, JANUARY 2022−JUNE 2025                 373

TABLE 512            INOTIV: EXPANSIONS, JANUARY 2022−JUNE 2025        374

TABLE 513            JSR CORPORATION: COMPANY OVERVIEW                 375

TABLE 514            JSR CORPORATION: PRODUCTS/SERVICES OFFERED             376

TABLE 515            JSR CORPORATION: DEALS, JANUARY 2022−JUNE 2025                378

TABLE 516            JSR CORPORATION: EXPANSIONS, JANUARY 2022−JUNE 2025                378

TABLE 517            BIOCYTOGEN: COMPANY OVERVIEW    380

TABLE 518            BIOCYTOGEN: PRODUCTS/SERVICES OFFERED                 381

TABLE 519            BIOCYTOGEN: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025            383

TABLE 520            BIOCYTOGEN: DEALS, JANUARY 2022−JUNE 2025        383

TABLE 521            BIOCYTOGEN: EXPANSIONS, JANUARY 2022−JUNE 2025                385

TABLE 522            SHANGHAI MODEL ORGANISMS CENTER, INC.: COMPANY OVERVIEW   387

TABLE 523            SHANGHAI MODEL ORGANISMS CENTER, INC.: PRODUCTS/SERVICES OFFERED               388

TABLE 524            SHANGHAI MODEL ORGANISMS CENTER, INC.: DEALS, JANUARY 2022−JUNE 2025            389

TABLE 525            TRANS GENIC INC.: COMPANY OVERVIEW                 390

TABLE 526            TRANS GENIC, INC.: PRODUCTS/SERVICES OFFERED             391

TABLE 527            TRANS GENIC, INC.: DEALS, JANUARY 2022−JUNE 2025                392

TABLE 528            HARBOUR BIOMED: COMPANY OVERVIEW                 393

TABLE 529            HARBOUR BIOMED: PRODUCTS/SERVICES OFFERED             394

TABLE 530            HARBOUR BIOMED: DEALS, JANUARY 2022−JUNE 2025                395

TABLE 531            HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025            397

TABLE 532            GENOWAY: COMPANY OVERVIEW           398

TABLE 533            GENOWAY: PRODUCTS/SERVICES OFFERED                 399

TABLE 534            GENOWAY: DEALS, JANUARY 2022−JUNE 2025                 401

TABLE 535            GEMPHARMATECH: COMPANY OVERVIEW                 402

TABLE 536            GEMPHARMATECH: PRODUCTS/SERVICES OFFERED             403

TABLE 537            GEMPHARMATECH: PRODUCT/SERVICE LAUNCHES, JANUARY 2022−JUNE 2025   404

TABLE 538            GEMPHARMATECH: DEALS, JANUARY 2022−JUNE 2025                405

TABLE 539            GEMPHARMATECH: EXPANSIONS, JANUARY 2022−JUNE 2025                405

TABLE 540            CYAGEN: COMPANY OVERVIEW                406

TABLE 541            CYAGEN: PRODUCTS/SERVICES OFFERED                 406

TABLE 542            CYAGEN: DEALS, JANUARY 2022−JUNE 2025                 407

TABLE 543            OZGENE PTY LTD.: COMPANY OVERVIEW                 408

TABLE 544            OZGENE PTY LTD.: PRODUCTS/SERVICES OFFERED             408

TABLE 545            OZGENE PTY. LTD: DEALS, JANUARY 2022−JUNE 2025                409

TABLE 546            TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW          410

TABLE 547            TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED               410

TABLE 548            TACONIC BIOSCIENCES, INC.: PRODUCT/SERVICE LAUNCHES,

JANUARY 2022−JUNE 2025            412

TABLE 549            TACONIC BIOSCIENCES, INC.: DEALS, JANUARY 2022−JUNE 2025                413

TABLE 550            TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2022−JUNE 2025            413

TABLE 551            TRANSCURE BIOSERVICES: COMPANY OVERVIEW          414

TABLE 552            TRANSCURE BIOSERVICES: PRODUCTS/SERVICES OFFERED               414

TABLE 553            TRANSCURE BIOSERVICES: DEALS, JANUARY 2022−JUNE 2025                415

TABLE 554            VIVO BIO TECH LTD.: COMPANY OVERVIEW                 416

TABLE 555            VIVO BIO TECH LTD.: PRODUCTS/SERVICES OFFERED             417

TABLE 556            INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW   418

TABLE 557            INGENIOUS TARGETING LABORATORY: PRODUCTS/SERVICES OFFERED               418

TABLE 558            JANVIER LABS: COMPANY OVERVIEW    420

TABLE 559            JANVIER LABS: PRODUCTS/SERVICES OFFERED                 420

TABLE 560            JANVIER LABS: DEALS, JANUARY 2022−JUNE 2025        423

TABLE 561            CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW          424

TABLE 562            CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED             425

TABLE 563            CHAMPIONS ONCOLOGY, INC.: DEALS, JANUARY 2022−JUNE 2025            425

TABLE 564            VITALSTAR BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW   426

TABLE 565            VITALSTAR BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED    426

TABLE 566            ONCODESIGN SERVICES: COMPANY OVERVIEW                 427

TABLE 567            CLEA JAPAN, INC.: COMPANY OVERVIEW                 428

TABLE 568            APPLIED STEMCELL: COMPANY OVERVIEW                 429

TABLE 569            CREATIVE ANIMODEL: COMPANY OVERVIEW                 430

TABLE 570            JOINN LABORATORIES (CHINA) CO., LTD.: COMPANY OVERVIEW   431

TABLE 571            CREATIVE BIOLABS: COMPANY OVERVIEW                 432

TABLE 572            CRESCENDO BIOLOGICS LIMITED: COMPANY OVERVIEW          433

TABLE 573            ARAGEN LIFE SCIENCES LTD.: BUSINESS OVERVIEW          434

TABLE 574            POLYGENE: BUSINESS OVERVIEW            435

TABLE 575            PHARMATEST: BUSINESS OVERVIEW      436

TABLE 576            MARSHALL BIORESOURCES: BUSINESS OVERVIEW          437

LIST OF FIGURES

FIGURE 1              MICE MODEL MARKET SEGMENTATION                 42

FIGURE 2              RESEARCH DESIGN         45

FIGURE 3              MICE MODEL MARKET: BREAKDOWN OF PRIMARIES          47

FIGURE 4              MICE MODEL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024  47

FIGURE 5              MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE

ANALYSIS-BASED ESTIMATION), 2024     48

FIGURE 6              ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES:

REVENUE SHARE ANALYSIS (2024)            49

FIGURE 7              MARKET SIZE VALIDATION FROM PRIMARY SOURCES             50

FIGURE 8              MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH                50

FIGURE 9              MICE MODEL MARKET: CAGR PROJECTIONS                 52

FIGURE 10            DATA TRIANGULATION METHODOLOGY                 53

FIGURE 11            MICE MODEL MARKET, BY MODEL TYPE & SERVICE,

2025 VS. 2030 (USD MILLION)      56

FIGURE 12            MICE MODEL MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)                57

FIGURE 13            MICE MODEL MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)      57

FIGURE 14            MICE MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)                58

FIGURE 15            GEOGRAPHIC SNAPSHOT OF MICE MODEL MARKET               59

FIGURE 16            RISING DEMAND FOR MOUSE CLINICAL TRIALS TO PROPEL MARKET      60

FIGURE 17            MODEL TYPE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024             61

FIGURE 18            CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       61

FIGURE 19            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD                62

FIGURE 20            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD                62

FIGURE 21            MICE MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          63

FIGURE 22            MICE MODEL MARKET: VALUE CHAIN ANALYSIS                 75

FIGURE 23            AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER,

2022–2024 (USD)                77

FIGURE 24            AVERAGE SELLING PRICE OF MODEL TYPES, BY REGION (USD)  78

FIGURE 25            MICE MODEL MARKET: ECOSYSTEM ANALYSIS                 79

FIGURE 26            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           86

FIGURE 27            PATENT APPLICATIONS IN MICE MODEL MARKET,

JANUARY 2014−DECEMBER 2024               88

FIGURE 28            MICE MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS            103

FIGURE 29            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MICE MODEL MARKET     105

FIGURE 30            KEY BUYING CRITERIA FOR END USERS                 106

FIGURE 31            INVESTMENT & FUNDING SCENARIO, 2022–2025                 107

FIGURE 32            AI-USE CASES IN MICE MODEL MARKET                 108

FIGURE 33            NORTH AMERICA: MICE MODEL MARKET SNAPSHOT          225

FIGURE 34            ASIA PACIFIC: MICE MODEL MARKET SNAPSHOT          261

FIGURE 35            REVENUE SHARE ANALYSIS FOR KEY COMPANIES, 2022–2024 (USD MILLION) 328

FIGURE 36            MICE MODEL MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 329

FIGURE 37            MICE MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2024,         332

FIGURE 38            MICE MODEL MARKET: COMPANY FOOTPRINT                 333

FIGURE 39            MICE MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 340

FIGURE 40            EV/EBITDA OF KEY VENDORS   343

FIGURE 41            YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK

BETA OF KEY VENDORS                343

FIGURE 42            MICE MODEL MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS            344

FIGURE 43            CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)             353

FIGURE 44            THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024)             360

FIGURE 45            INOTIV: COMPANY SNAPSHOT (2024)     370

FIGURE 46            JSR CORPORATION: COMPANY SNAPSHOT (2023)    376

FIGURE 47            BIOCYTOGEN: COMPANY SNAPSHOT (2024)                 381

FIGURE 48            SHANGHAI MODEL ORGANISMS CENTER, INC.: COMPANY SNAPSHOT (2024)      387

FIGURE 49            TRANS GENIC INC.: COMPANY SNAPSHOT (2024)    391

FIGURE 50            HARBOUR BIOMED: COMPANY SNAPSHOT (2024)    394

FIGURE 51            GENOWAY: COMPANY SNAPSHOT (2024)                 398

FIGURE 52            GEMPHARMATECH: COMPANY SNAPSHOT (2024)    402

FIGURE 53            VIVO BIO TECH LTD.: COMPANY SNAPSHOT (2023)    416

FIGURE 54            CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2023)             424

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧